skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors

Review

(2620) Views  (867) Full article downloads

Authors: Divina G Brillante, Anthony J O’Sullivan, Laurence G Howes

Published Date December 2008 Volume 2009:5 Pages 73 - 78
DOI: http://dx.doi.org/10.2147/VHRM.S3784

Divina G Brillante1, Anthony J O’Sullivan1, Laurence G Howes2

1St. George Clinical School, University of New South Wales, Kogarah, NSW, Australia; 2Department of Pharmacology and Therapeutics and Department of Cardiology, Griffith and Bond University, Gold Coast Hospital, Southport, QLD, Australia

Abstract: The insulin resistance syndrome (INSR) is associated with increased cardiovascular risk, and affects up to 25% of the Australian population aged >20 years. Increased arterial stiffness has been proposed as a common pathway by which INSR leads to increased cardiovascular risk. We have reviewed the role of nitric oxide (NO) and angiotensin II receptors in the modulation of arterial stiffness in the setting of insulin resistance. There is emerging evidence that early stages of INSR may be characterized by increased basal nitric oxide activity and increased activity of non-NO vasodilators such as endothelial derived hyperpolarization factor (EDHF) which is manifest by reduced arterial stiffness. Depletion of NO or ineffectiveness of NO mediated vasodilator mechanisms associated with the progression of INSR to type 2 diabetes may result in increased arterial stiffness, which predicts the development of cardiovascular disease. Thus in the early stages of INSR, increased NO and EDHF activity may represent compensatory mechanisms to early vascular damage. The renin-angiotensin system is activated in diseased vascular beds, with up regulation of the two known angiotensin II receptors: the angiotensin II type 1 receptor (AT1R) and the angiotensin II type 2 receptor (AT2R). Increased AT1R mediated activity in the vasculature is central to the development of increased arterial stiffness and is enhanced in INSR states. AT2R activity is increased in early in INSR and may contribute to the apparent increase in basal NO activity. AT1R blockade may therefore be valuable treatment for early INSR as antagonism of AT1 receptors would allow angiotensin II to act unopposed at AT2 receptors.

Keywords: arterial stiffness, insulin resistance, nitric oxide, AT1 receptor, AT2 receptor, diabetes, insulin resistance, obesity








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Arterial stiffness, hypertension, and rational use of nebivolol
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care
Cardiac risk stratification: Role of the coronary calcium score
The threshold elicited motor response via an in situ femoral nerve catheter predicts analgesia following total knee replacement
Weight loss in elderly women in low-level care and its association with transfer to high-level care and mortality
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women
Evolving role of platelet function testing in coronary artery interventions
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University